UY27585A1 - Cis - imidazolinas - Google Patents

Cis - imidazolinas

Info

Publication number
UY27585A1
UY27585A1 UY27585A UY27585A UY27585A1 UY 27585 A1 UY27585 A1 UY 27585A1 UY 27585 A UY27585 A UY 27585A UY 27585 A UY27585 A UY 27585A UY 27585 A1 UY27585 A1 UY 27585A1
Authority
UY
Uruguay
Prior art keywords
imidazolinas
cis
formula
peptide
inhibit
Prior art date
Application number
UY27585A
Other languages
English (en)
Inventor
Binh Thanh Vu
Emil Aijun Liu
Norman Kong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27585A1 publication Critical patent/UY27585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

la presente invención proporciona compuestos de acuerdo con la fórmula I y fórmula II y sales y ésteres farmacéuticamente aceptable de los mismos, con la denominaciones proporcionadas aqui y que inhiben la interacción de la proteina MDM2 con un péptico de tipo p53 y con actividad antiproliferativa.
UY27585A 2001-12-18 2002-12-17 Cis - imidazolinas UY27585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34171401P 2001-12-18 2001-12-18
US39087402P 2002-06-21 2002-06-21

Publications (1)

Publication Number Publication Date
UY27585A1 true UY27585A1 (es) 2003-06-30

Family

ID=26992625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27585A UY27585A1 (es) 2001-12-18 2002-12-17 Cis - imidazolinas

Country Status (19)

Country Link
US (1) US6734302B2 (es)
EP (1) EP1458380B1 (es)
JP (1) JP4477351B2 (es)
KR (2) KR100650966B1 (es)
CN (1) CN100486969C (es)
AT (1) ATE389400T1 (es)
AU (1) AU2002366278B2 (es)
BR (1) BR0215157A (es)
CA (1) CA2469187C (es)
DE (1) DE60225719T2 (es)
ES (1) ES2301717T3 (es)
MX (1) MXPA04005906A (es)
PA (1) PA8561901A1 (es)
PE (1) PE20030895A1 (es)
PL (1) PL370823A1 (es)
RU (1) RU2305095C2 (es)
TW (1) TW200301112A (es)
UY (1) UY27585A1 (es)
WO (1) WO2003051359A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20040204410A1 (en) * 2002-06-21 2004-10-14 Norman Kong CIS-imidazolines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
AU2004253245B2 (en) * 2003-06-17 2010-02-11 F. Hoffmann-La Roche Ag CIS-imidazolines as MDM2 inhibitors
CN100465163C (zh) * 2003-06-17 2009-03-04 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三芳基-咪唑啉类化合物
KR100832277B1 (ko) * 2004-05-18 2008-05-26 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) * 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
SI1809622T1 (sl) 2004-09-22 2010-11-30 Janssen Pharmaceutica Nv Inhibitorji interakcije med MDM in P
KR101139263B1 (ko) 2005-03-16 2012-05-16 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의그의 용도
WO2007063013A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
WO2007082805A1 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
ATE470665T1 (de) 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
WO2008014216A1 (en) 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
KR20090090383A (ko) 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
EP2185541B1 (en) 2007-08-06 2015-01-28 Janssen Pharmaceutica, N.V. Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
CA2701932C (en) 2007-10-09 2015-10-20 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
PT2380892E (pt) 2009-01-16 2014-06-09 Daiichi Sankyo Co Ltd Derivado de imidazotiazole compreendendo uma estrutura de anel prolina
EP2393801B1 (en) 2009-02-04 2017-07-12 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
EP2470502A1 (en) * 2009-08-26 2012-07-04 Novartis AG Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
BR112012011317A2 (pt) 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9266860B2 (en) * 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
JP2014507384A (ja) 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
US8815926B2 (en) * 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
CN117679487A (zh) 2013-03-15 2024-03-12 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
PT3004112T (pt) 2013-05-28 2017-12-11 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença
PT3004108T (pt) 2013-05-28 2018-01-24 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
CN106163557B (zh) 2014-01-28 2020-07-14 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
CN113788818A (zh) 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
AU2017418538B2 (en) 2017-06-16 2021-10-21 Unity Biotechnology, Inc. Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
CA3112591A1 (en) 2018-10-08 2020-04-16 The Regents Of The University Of Michigan Small molecule mdm2 protein degraders
CN115776887A (zh) 2020-03-19 2023-03-10 凯麦拉医疗公司 Mdm2降解剂和其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023191513A1 (ko) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 당 결합된 이미다졸린 유도체 및 이의 용도
US11981640B1 (en) 2023-11-08 2024-05-14 King Faisal University 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3-hydroxy-4-methoxyphenyl)-1H-imidazole as an antimicrobial compound
US11926597B1 (en) 2023-11-08 2024-03-12 King Faisal University 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3,4-dimethoxyphenyl)-1H-imidazole as an antimicrobial compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182268A (en) * 1989-11-22 1993-01-26 Marion Merrell Dow, Inc. Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole
EP0543930A1 (en) 1990-08-17 1993-06-02 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
AU1199600A (en) * 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands

Also Published As

Publication number Publication date
JP4477351B2 (ja) 2010-06-09
CN1606439A (zh) 2005-04-13
EP1458380B1 (en) 2008-03-19
KR20040068277A (ko) 2004-07-30
TW200301112A (en) 2003-07-01
PE20030895A1 (es) 2003-10-25
ES2301717T3 (es) 2008-07-01
PA8561901A1 (es) 2003-11-12
CA2469187A1 (en) 2003-06-26
KR100650966B1 (ko) 2006-11-30
RU2004122414A (ru) 2005-06-27
US20030153580A1 (en) 2003-08-14
MXPA04005906A (es) 2004-09-13
JP2005511766A (ja) 2005-04-28
CA2469187C (en) 2012-07-17
WO2003051359A1 (en) 2003-06-26
DE60225719D1 (de) 2008-04-30
AU2002366278A1 (en) 2003-06-30
ATE389400T1 (de) 2008-04-15
DE60225719T2 (de) 2009-04-23
PL370823A1 (en) 2005-05-30
EP1458380A1 (en) 2004-09-22
RU2305095C2 (ru) 2007-08-27
KR20060096513A (ko) 2006-09-11
CN100486969C (zh) 2009-05-13
US6734302B2 (en) 2004-05-11
BR0215157A (pt) 2004-10-19
AU2002366278B2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
PA8561901A1 (es) Cis-imidazolinas
MXPA04005880A (es) Cis-imidazolinas como inhibidores de la mdm2.
TW200600501A (en) Novel cis-imidazolines
MX2009011019A (es) Difenil-dihidro-imidazopiridinonas.
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
FI950309A0 (fi) Proliiniamidijohdannaisia
ATE284413T1 (de) Therapeutische peptid derivate
NO20034660D0 (no) Spiropyrazolforbindelser
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
CY1110446T1 (el) Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοϊκου οξεος-(4’-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια πολλαπλης σκληρωσης
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
ATE353336T1 (de) Neues peptid mit angiotensinkonvertase hemmender wirkung
ATE465729T1 (de) Cis-imidazoline als mdm2-hemmer
MXPA05013279A (es) Cis-2,4,5-triaril-imidazolinas.
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
ATE401901T1 (de) Antikrebs- und antivirale zusammensetzung
NO994135L (no) Kinoksalindioner
FR2858769B1 (fr) Utilisation d'un peptide comme principe actif amincissant
DE60022047D1 (de) Antivirale therapie
ECSP961754A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9539)
ECSP961756A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9250)
ECSP961755A (es) Agentes antifungicos de peptidos ciclicos (caso x-9249)
ATE360432T1 (de) Peptid zur behandlung von nervenerkrankungen
ATE270886T1 (de) Antivirale therapie

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150415